Agreement with Mawdsley Brooks Brazil
Proveca enters an exclusive agreement with Mawdsley Brooks Brazil, part of global pharmaceutical services provider Mawdsleys, to commercialise and distribute Sialanar® in Brazil.
William Sanders, Group CEO, Mawdsley-Brooks & Co. Ltd and Simon Barter, Chief Commercial Officer, Proveca Ltd signing the agreement.
Under the terms of the agreement, Mawdsley Brooks Brazil will have exclusive rights to market and distribute Sialanar® in Brazil. It is estimated that approximately 13,000 children with neurodisabilities suffer from sialorrhoea in the country today.
Sialanar® (320 mcg/ml glycopyrronium, oral solution) received a European Paediatric Use Marketing Authorisation (PUMA) on 15th September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
Full product information on Sialanar® can be found here: https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar®#product-information-section
Dr Simon Bryson, CEO and founder of Proveca Ltd, commented
“We are delighted to announce this agreement with Mawdsley Brooks Brazil to make Sialanar®® available to children with neurodisabilities who suffer from sialorrhoea. As in many countries across the world there is a high unmet need to manage this condition and improve the quality of the lives of patients and their carers. We are looking forward to working with Mawdsley Brooks Brazil who can offer their first-class capabilities to support the launch of Sialanar®® in Brazil. This is another significant agreement outside the EU for Sialanar® as part of our commercialisation strategy to optimise access of our products across the world.”
William Sanders, Group CEO of Mawdsleys Group commented
“This is an exciting opportunity for Mawdsley Brooks Brazil to in-license another specialty care medicine into its portfolio. Once commercialised, we believe that Sialanar® will give an important new treatment option for paediatric patients with sialorrhea in Brazil. We look forward to creating access to this new medicine in Brazil through our in-country regulatory, distribution and market access capabilities and to working closely with Proveca on other such projects in the future.”
About Proveca Ltd
Proveca Ltd is a pharmaceutical company based in Europe specialising in the development and licensing of medicines to address the unmet medical needs of children. The team at Proveca are seeking to improve the lives of children, many of whom require long-term drug treatment for chronic conditions. Working with clinicians, parents, carers and children, Proveca are leading the way in providing licenced, clinically proven, medicines that are tailored to the specific needs of children.
For further information about Proveca Ltd, please visit www.proveca.com
About Mawdsleys
Founded in 1825, Mawdsleys is a global pharmaceutical service provider offering a wide range of services to the pharmaceutical industry and healthcare sector. The business currently employs over 600 people based in strategically located offices and distribution centres across the world. Mawdsley Brooks Brazil specialises in commercialising new rare disease and specialty care medicines in Brazil.
For further information about Mawdsleys, please visit www.mawdsleys.co.uk
UK-SIA-22-0061
Created May 2022